Kievit Peter C, Brouwer Marc A, Veen Gerrit, Karreman Aart J, Verheugt Freek W A
Heartcenter, University Medical Center Nijmegen, Nijmegen, The Netherlands.
Am Heart J. 2004 Nov;148(5):826-33. doi: 10.1016/j.ahj.2004.05.043.
After successful thrombolysis, a high-grade stenosis at 24-hour angiography is strongly predictive of reocclusion and is often believed to result in high reinfarction rates. However, routine angioplasty did not reduce death or reinfarction in past trials. Systematic angiographic follow-up shows that reocclusion often occurs without clinical reinfarction. This study investigates whether the increased risk for reocclusion associated with a high-grade lesion translates into impaired clinical outcome.
In the ischemia-guided Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis (APRICOT-1) trial, 240 patients with ST-elevation MI who had an open infarct artery 24 hours after thrombolysis had 3-month repeat angiography to assess reocclusion, with clinical follow-up at 3 months and 3 years.
On the basis of the optimal discriminative stenosis severity, the reocclusion rate was 40% (47/118) in patients with a high-grade residual stenosis and 16% (20/122) in patients with a low-medium-grade lesion (risk ratio [RR], 2.43; 95% CI, 1.54-3.84; P <.01). Three-month death and reinfarction rates did not differ: 6% (7/118) versus 9% (11/122; RR, 0.66; 95% CI, 0.26-1.64; P = not significant). Systematic angiographic follow-up revealed that reocclusion of a high-grade lesion occurred in the absence of clinical reinfarction in 85% (40/47) of patients, as compared with 45% (9/20) in patients with a low-medium-grade stenosis (RR, 1.89; 95% CI, 1.15-3.12; P <.01). Despite an independent association with reocclusion, a high-grade stenosis was not predictive of either short- or long-term death and reinfarction.
After successful thrombolysis and adopting an ischemia-guided revascularization strategy, patients with a high-grade stenosis experience death/reinfarction rates similar to that of patients with a low-medium-grade lesion. This is true despite a 2- to 3-fold higher risk for reocclusion. The finding that reocclusion of a high-grade lesion often occurs without clinical reinfarction explains the absence of a relationship between a severe stenosis and death/reinfarction. Appreciation of these observations may contribute to an optimal design of a future randomized trial to re-evaluate the impact of a routine invasive strategy.
成功溶栓后,24小时血管造影显示的高度狭窄强烈预示着再闭塞,且通常认为会导致高再梗死率。然而,在过去的试验中,常规血管成形术并未降低死亡率或再梗死率。系统性血管造影随访显示,再闭塞常发生但无临床再梗死。本研究调查与高度病变相关的再闭塞风险增加是否会转化为临床结局受损。
在缺血指导的冠状动脉溶栓预防再闭塞的抗栓治疗(APRICOT-1)试验中,240例ST段抬高型心肌梗死患者在溶栓后24小时梗死动脉开通,进行3个月的重复血管造影以评估再闭塞情况,并在3个月和3年时进行临床随访。
根据最佳鉴别狭窄严重程度,高度残余狭窄患者的再闭塞率为40%(47/118),低-中度病变患者为16%(20/122)(风险比[RR],2.43;95%CI,1.54-3.84;P<.01)。3个月时的死亡率和再梗死率无差异:分别为6%(7/118)和9%(11/122;RR,0.66;95%CI,0.26-1.64;P=无显著性差异)。系统性血管造影随访显示,85%(40/47)的高度病变再闭塞患者无临床再梗死,而低-中度狭窄患者为45%(9/20)(RR,1.89;95%CI,1.15-3.12;P<.01)。尽管高度狭窄与再闭塞独立相关,但它并不能预测短期或长期的死亡和再梗死。
成功溶栓并采用缺血指导的血运重建策略后,高度狭窄患者的死亡/再梗死率与低-中度病变患者相似。尽管再闭塞风险高出2至3倍,但情况依然如此。高度病变再闭塞常发生但无临床再梗死这一发现解释了严重狭窄与死亡/再梗死之间不存在关联。认识到这些观察结果可能有助于未来随机试验的优化设计,以重新评估常规侵入性策略的影响。